Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 5,056 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Olfactory Disorder, Anosmia, Viral Infection, Theophylline Causing Adverse Effects in Therapeutic Use, Smell Disorder
Interventions: Theophylline, Saline Nasal; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Inflammation
Interventions: Maqui berry/omeg-3 fatty acids, Placebos; Dietary Supplement
Lead sponsor: Arizona State University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: EGCG 300 mg, Placebo for EGCG 300 mg, EGCG 600 mg, Placebo for EGCG 600 mg; Drug
Lead sponsor: Hal Chapman; Other
Eligibility: 40 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia

Conditions: Bird Flu, Influenza
Interventions: Placebo, Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1; Other · Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Lexington, Kentucky • Kansas City, Missouri • Rochester, New York + 1 more

Conditions: Obsessive-Compulsive Disorder
Interventions: dextro-amphetamine, Sham Comparison; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lymphoma, Non-Hodgkin
Interventions: Cyclophosphamide, BCNU, Etoposide, Filgrastim, Antithymocyte globulin, Cyclosporine, Mycophenolate mofetil, Rituximab, Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation, CD34+ Cells, Solu-Medrol; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Fibromyalgia
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 102
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 81 more

Conditions: Drug Dependence
Interventions: Cycloserine, Diltiazem, Gabapentin, Isradipine, Naloxone, Nifedipine, Placebo, Saline, Verapamil; Drug · Device
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Schizophrenia or Schizoaffective
Interventions: Lumateperone Capsule, Lumateperone LAI; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Los Alamitos, California • Atlanta, Georgia • Marlton, New Jersey

Conditions: Cancer
Interventions: Ipatasertib (capsule), Ipatasertib (tablet); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: SKL24741, Placebo; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Interventions: CC-223, erlotinib, CC-223, oral azacitidine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • New York, New York + 4 more

Conditions: Alzheimer s Disease
Interventions: Terazosin (Hytrin), Placebo; Drug · Other
Lead sponsor: Qiang Zhang; Other
Eligibility: 50 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: ALK Fusion-positive Solid or CNS Tumors
Interventions: Alectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 7
States / cities: Palo Alto, California • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more

Conditions: Coronavirus Infection
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis (MS)
Interventions: Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 6
States / cities: Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more

Conditions: Graft Versus Host Disease, Hematologic Neoplasms
Interventions: Busulfan, Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Danicopan, Cyclosporine, Tacrolimus, Calcium Carbonate, Aluminum/Magnesium Hydroxide/Simethicone, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Sjogren's Syndrome
Interventions: Placebo, RO5459072; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Beverly Hills, California • Denver, Colorado • Baton Rouge, Louisiana + 9 more

Conditions: Colitis, Ulcerative, Crohn Disease
Interventions: Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Cypress, California • Miami, Florida

Conditions: Healthy Volunteers
Interventions: MN-166; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Cypress, California

Conditions: Cognitive Ability, General
Interventions: SageXtra, Placebo; Dietary Supplement
Lead sponsor: ESM Technologies, LLC; Industry
Eligibility: 40 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Posttraumatic Stress Disorder With Attention Defic
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Premenstrual Syndrome, Menstrual Symptoms
Interventions: Two Moons Seed Cycling Capsules; Dietary Supplement
Lead sponsor: Superlune Inc. d/b/a Two Moons Health; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Search by objective public record fields.

Smell Changes & Efficacy of Nasal Theophylline

Maqui Berry Extract and Omega-3 Fatty Acids for Cytokine Reduction

Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia

Drug Discrimination in Methadone-Maintained Humans Study 1

Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Terazosin And Metabolic Engagement in Alzheimer's Disease

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Optimizing PTCy Dose and Timing

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

Effect of Sage Extract Supplementation on Cognitive Function in Middle-Aged Men and Women

Atomoxetine and Executive Function in PTSD

Effects of Seed Cycling Capsules on Premenstrual Syndrome Symptoms and Menstrual Cycle Length